Skip to Main Content
Skip Nav Destination

A Dual AR Degrader–Inhibitor for Prostate Cancer

May 8, 2024

Small-molecule inhibitors of the androgen receptor are still a treatment mainstay for advanced prostate cancer, but increasingly, the field is moving toward AR degraders for complete target elimination. An investigational candidate, BMS-986365, has shown preliminary promise as a dual AR degrader and inhibitor. Through a screening platform, researchers are also homing in on a new compound that selectively targets the splice variant AR-V7, a known culprit in resistance to standard care for this disease.

You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal